Healthcare / Medical DevicesCanadian Sec
$0.04
-0.01 (-11.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-678852.00 · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
89.1%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-1.2M · FCF $-36872.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $35020.00 | $134820.00 |
| Net Income | $-1.2M | $-1.2M | $-2.0M | $-2.1M | $-1.9M |
| EBITDA | $-1.0M | $-1.0M | $-1.8M | $-1.9M | $-1.8M |
| EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Gross Margin | — | — | — | 76.0% | 62.9% |
| Operating Margin | — | — | — | -5896.3% | -1396.1% |
| Net Margin | — | — | — | -5904.5% | -1396.1% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | -0.25 | — |
| Current Ratio | 0.34 | 0.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-36872.00 | $-36872.00 | $-1.6M | $-678852.00 | $-2.0M |
| Returns | |||||
| ROE | 89.1% | 89.1% | 1386.1% | 1348.0% | -212.2% |
| Valuation | |||||
| P/B | — | — | — | — | 14.60 |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | -74.0% | — |
| EPS Growth | 42.9% | 42.9% | 22.2% | -5.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+60.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
+60.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.